MedTrace Logo

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

NCT00290745 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2020-12-04

Study results available
· View outcomes & findings →

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.

PURPOSE: This clinical trial is studying how well tamoxifen or letrozole work in treating women with ductal carcinoma in situ.

Conditions

Interventions

DRUG

letrozole

DRUG

tamoxifen citrate

PROCEDURE

conventional surgery

PROCEDURE

neoadjuvant therapy

Sponsors & Collaborators

Principal Investigators

  • E. Shelley Hwang, MD, MPH · University of California, San Francisco

  • Frederic M. Waldman, MD, PhD · University of California, San Francisco

  • Nola M. Hylton, PhD · University of California, San Francisco

  • Rita Mukhtar, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-19
Primary Completion
2009-07-31
Completion
2011-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290745 on ClinicalTrials.gov